IMMUNOVANT, INC. (IMVT) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $10.14M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $10.14M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $10.14M |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 117.10M USD | Liabilities |
| Borrowing debt | (m) | |
| Amounts owed to suppliers | 10.14M USD | Accounts Payable, Current |
| Total deferred revenue | (m) | |
| Deferred revenue due within one year | (m) | |
| Deferred revenue due after one year | (m) | |
| Reported other obligations due within one year | (m) | Other Liabilities, Current |
| Reported other noncurrent obligations | (m) | |
| Deferred revenue included in other noncurrent obligations | (m) |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Obligation categories | (m) |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $10.14M | (m) | (m) | (m) | $117.10M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $7.54M | (m) | $175.00K | (m) | $104.42M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $8.62M | (m) | (m) | (m) | $66.26M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $6.92M | (m) | (m) | (m) | $63.25M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $7.84M | (m) | (m) | (m) | $52.90M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $17.66M | (m) | $273.00K | (m) | $68.78M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $19.82M | (m) | (m) | (m) | $68.31M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $20.73M | (m) | (m) | (m) | $66.65M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $11.04M | (m) | (m) | (m) | $45.02M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $7.16M | (m) | $15.00K | (m) | $48.61M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $3.91M | (m) | (m) | (m) | $32.10M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $7.51M | (m) | (m) | (m) | $40.26M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $26.46M | (m) | (m) | (m) | $51.36M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $1.35M | (m) | (m) | (m) | $43.34M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $14.00M | (m) | (m) | (m) | $41.56M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $7.46M | (m) | (m) | (m) | $32.40M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $1.07M | (m) | (m) | (m) | $22.16M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $18.63M | (m) | (m) | (m) | $45.74M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $3.83M | (m) | (m) | (m) | $38.03M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $4.24M | (m) | (m) | (m) | $30.34M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $3.11M | (m) | (m) | (m) | $22.50M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $2.43M | (m) | (m) | (m) | $21.01M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $2.10M | (m) | (m) | (m) | $18.88M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $5.79M | (m) | (m) | (m) | $15.49M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $8.01M | (m) | (m) | (m) | $22.52M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $1.19M | (m) | (m) | (m) | $15.32M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $2.81M | (m) | (m) | (m) | $14.76M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | $4.36M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | $4.12M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $206.00K | (m) | (m) | (m) | $6.49M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | $380.45K | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |